An Open-label, Randomized, Parallel-group, Single Dose Study to Compare the Bioavailability of Subcutaneous Injections in the Arm, Thigh, and Abdomen and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of RO7239361 in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2018
At a glance
- Drugs Talditercept alfa (Primary)
- Indications Duchenne muscular dystrophy
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb; Roche
- 29 Jun 2018 Status changed from recruiting to completed.
- 02 Aug 2017 Planned End Date changed from 1 Sep 2017 to 30 Sep 2017.
- 02 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Sep 2017.